



Jul 24, 2021

# Thromboelastometry measurements in severe and non-severe COVID-19 patients

Rodrigo Aires<sup>1</sup>, Alexandre A. de S. M. Soares<sup>1</sup>, Ana Paula M. Gomides<sup>2</sup>, Andre M. Nicola<sup>1</sup>, Andrea Teixeira-Carvalho<sup>3</sup>, Dayde Lane M. da Silva<sup>4</sup>, Eliana T. de Góis<sup>1</sup>, Flávia D. Xavier<sup>1</sup>, Francielle P. Martins<sup>1</sup>, Gabriela P. J. Santos<sup>1</sup>, Heide Luise Schulte<sup>5</sup>, Isabelle S. Luz<sup>5</sup>, Laila S. Espíndola<sup>1</sup>, Laurence R. do Amaral<sup>6</sup>, Liza F. Felicori<sup>7</sup>, Luciana A. Naves<sup>1</sup>, Maíra R. M. de Carvalho<sup>1</sup>, Matheus de S. Gomes<sup>6</sup>, Otávio T. Nóbrega<sup>1</sup>, Patrícia Albuquerque<sup>8</sup>, Wagner Fontes<sup>5</sup>, Ciro M. Gomes<sup>1</sup>, Patrícia S. Kurizky<sup>1</sup>, Cleandro P. Albuquerque<sup>1</sup>, Olindo A. Martins-Filho<sup>3</sup>, Licia Maria H. da Mota<sup>1</sup>

<sup>1</sup>Faculdade de Medicina da Universidade de Brasília, Distrito Federal, Brazil; <sup>2</sup>CEUB; <sup>3</sup>FIOCRUZ; <sup>4</sup>FCS UnB; <sup>5</sup>ICB UnB; <sup>6</sup>UFU; <sup>7</sup>UFMG; <sup>8</sup>UnB Ceilândia

1 Works for me



Share

[dx.doi.org/10.17504/protocols.io.bwvbp2n](https://dx.doi.org/10.17504/protocols.io.bwvbp2n)

## TARGET



Rodrigo Aires

## ABSTRACT

In patients with severe forms of COVID-19, thromboelastometry has been reported to display a hypercoagulant pattern. However, an algorithm to differentiate severe COVID-19 patients from nonsevere patients and healthy controls based on thromboelastometry parameters has not been developed. Forty-one patients over 18 years of age with positive qRT-PCR for SARS-CoV-2 were classified according to the severity of the disease: nonsevere (NS, n=20) or severe (S, n=21). A healthy control (HC, n=9) group was also examined. Blood samples from all participants were tested by [extrinsic \(EXTEM\), intrinsic \(INTEM\), non-activated \(NATEM\) and functional assessment of fibrinogen \(FIBTEM\) assays of thromboelastometry](#). The thrombodynamic potential index (TPI) was also calculated. Severe COVID-19 patients exhibited a thromboelastometry profile with clear hypercoagulability, which was significantly different from the NS and HC groups. Nonsevere COVID-19 cases showed a trend to thrombotic pole. The NATEM test suggested that nonsevere and severe COVID-19 patients presented endogenous coagulation activation (reduced clotting time and clot formation time). TPI data were significantly different between the NS and S groups. The maximum clot firmness profile obtained by FIBTEM showed moderate/elevated accuracy to differentiate severe patients from NS and HC. A decision tree algorithm based on the FIBTEM-MCF profile was proposed to differentiate S from HC and NS. Thromboelastometric parameters are a useful tool to differentiate the coagulation profile of nonsevere and severe COVID-19 patients for therapeutic intervention purposes.

## DOI

[dx.doi.org/10.17504/protocols.io.bwvbp2n](https://dx.doi.org/10.17504/protocols.io.bwvbp2n)

## EXTERNAL LINK

<https://dx.doi.org/10.2196/24211>

#### PROTOCOL CITATION

Rodrigo Aires, Alexandre A. de S. M. Soares, Ana Paula M. Gomides, Andre M. Nicola, Andrea Teixeira-Carvalho, Dayde Lane M. da Silva, Eliana T. de Góis, Flávia D. Xavier, Francielle P. Martins, Gabriela P. J. Santos, Heide Luise Schulte, Isabelle S. Luz, Laila S. Espíndola, Laurence R. do Amaral, Liza F. Felicori, Luciana A. Naves, Maíra R. M. de Carvalho, Matheus de S. Gomes, Otávio T. Nóbrega, Patrícia Albuquerque, Wagner Fontes, Ciro M. Gomes, Patrícia S. Kurizky, Cleandro P. Albuquerque, Olindo A. Martins-Filho, Licia Maria H. da Mota 2021. Thromboelastometry measurements in severe and non-severe COVID-19 patients .

**protocols.io**

<https://dx.doi.org/10.17504/protocols.io.bwvbp2n>



#### FUNDERS ACKNOWLEDGEMENT

Laila Espíndola TED 74/2016 & TED 42/2017

#### MANUSCRIPT CITATION please remember to cite the following publication along with this protocol

Kurizky P, Nobrega OT, Soares A, Aires RB, Albuquerque CP, Nicola AM, et al. Molecular and Cellular Biomarkers of COVID-19 Prognosis: Protocol for the Prospective Cohort TARGET Study. JMIR Res Protoc. 2021;10(3):e24211.

#### KEYWORDS

thromboelastometry, COVID-19, NATEM

#### LICENSE

————— This is an open access protocol distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

#### CREATED

Jul 24, 2021

#### LAST MODIFIED

Jul 24, 2021

#### PROTOCOL INTEGER ID

51843

#### GUIDELINES

1) ROTEMdelta2.8.0.01.EN\_mail\_ [Internet]. 2016 [cited june of 2020]. Available from: [https://www.rotem.de/wp-content/uploads/2016/08/ROTEMdelta2.8.0.01.EN\\_mail\\_.pdf](https://www.rotem.de/wp-content/uploads/2016/08/ROTEMdelta2.8.0.01.EN_mail_.pdf).

[ROTEM-delta-US-Operating-Manual-Part-12\(1\).pdf](#)

2) Calatzis A GK, Spannagl M, Vorweg M. <ROTEM\_Analysis\_delta\_platelet\_EN\_2016-09-website.pdf>. 2016.

[ROTEM-delta-and-platelet\\_EN\\_2016\\_V01-1\(3\).pdf](#)

3) Adamzik M, Eggmann M, Frey UH, Gorlinger K, Bocker-Preuss M, Marggraf G, et al. Comparison of thromboelastometry with procalcitonin, interleukin 6, and C-reactive protein as diagnostic tests for severe sepsis in critically ill adults. Crit Care. 2010;14(5):R178.

[Adamzik-2010-Comparison of thromboelastometry.pdf](#)

## MATERIALS TEXT

Reagents and materials used in all tests.

Purchased from WERFEN Diagnostics Solutions for Life in Brazil.

- 1) star-tem 10: Batch 42280701
- 2) r ex-tem 10x10: Batch 42311401
- 3) in-tem: Batch 42340101
- 4) fib-tem 10x5: Batch 42331701
- 5) ROTROL N: Batch 42318601
- 6) ROTROL P: Batch L 42304601
- 7) Cup & Pin pro: Batch M19061
- 8) TIPTRAY Box eLine 10-320 µL: Batch PR155278

## SAFETY WARNINGS

As dealing with COVID-19 infected blood samples, maintain during the complete measurement time, biological hazards protection devices: gloves, masks and aprons.

## BEFORE STARTING

Check availability of blood sample  
Check availability of reagents and actual temperature  
Check availability of cups, pins, pipette tips and pipette

### Inclusion criteria

- 1 COVID-19 patients treated during the pandemic in midwestern Brazil (Hospital Regional da Asa Norte and Hospital Universitário de Brasília, Brasília, DF, Brazil (between August 1st and September 30th, 2020) were included. Confirmatory diagnosis was based on positive SARS-CoV-2 infection results in oropharyngeal swabs by quantitative real-time polymerase chain reaction (qRT-PCR).

### Exclusion criteria

- 2
  1. under 18 years old.
  2. pregnancy.
  3. thrombophilia or previous thromboembolic events.
  4. previous use of anticoagulants.
  5. previous use of antiplatelet drugs
  6. surgical procedures in the last 4 weeks.
  7. hereditary coagulopathies and
  8. psychiatric diseases that impaired the understanding of the informed consent form.

### Sample calculation

- 3 The sample size calculation was carried out based on a previous study of NATEM curves in septic patients and healthy controls (Adamzik, 2010).

The G\*Power software version 3.1.9.6 was used:

- Test family: t tests
- Statistical test: Means: Difference between two independent means (two groups)
- Type of power analysis: A priori: Compute required sample size - given alfa, power, and effect size
- Tail: Two
- alfa err prob: 0,05
- power (1-beta err prob): 0,95,
- effect size: d = 1.664101
- Determine:
  - n1=n2
  - Mean group 1: 229
  - Mean group 2: 259
  - SD group 1: 19
  - SD group 2: 17
- yielded a minimal sample of 11 patients in each group.
- No data was excluded.

#### Patient inclusion

8w

- 4 Patients with confirmed COVID-19 infection by SARS-CoV-2 PCR were offered participation in the study. Participation in the study was not necessary for receiving the proper disease treatment. Those who decided to participate were informed about the study, the possibility to abandon it at any time and received all information for a proper Informed Consent, which was sent by electronic form.

#### Patient classification

- 5 Patients were classified according to disease severity as follows:
 

Severe: patients needing hospitalization due to at least one of the following: dyspnea (respiratory rate >30 respiratory incursions per minute), SpO2 <93% in room air, PaO2/FiO2<300mmHg, admission to the intensive care unit or need for mechanical ventilation.

Non-severe: patients not necessitating hospitalization

#### Blood sampling

- 6 Citrated whole blood is collected of each research participant (enough to complete standard coagulation tests tubes:4 ml) and kept at room temperature.
 

When not possible to make measurements immediately, the samples must be preheated for 5–10 min before measurement in the sample preheating station of the ROTEM® delta.

#### Quality control

- 7
  - 1) Quality control must be performed weekly, using standardized system controls ROTROL N and ROTROL P.
  - 2) Daily maintenance: outer surface, cup holder, pipette and filter

8

9 3) Weekly maintenance: replace pipette filter

10 4) Quarterly maintenance: device temperature (between 36oC and 38oC) and CCD chip (amplitude, centre and variance)

#### Instrument preparation

11 1) All reagents must be taken from refrigerator prior to use

12 2) The tests must be started only after target temperature are achieved

13 3) Take the cup with the pin in it from the storage box

14 4) Push the pin in the cup onto the axis chosen for the measurement.

15 5) Place the cup with its opening facing upwards into the appropriate preheated cupholder.

16 6) Place the cup holder onto the temperature-controlled work area again.

17 7) Push and fix the cup in the cup holder using the MC Rod.

#### EXTEM exam

18 1) Reagents: r ex-tem® and star-tem®

19 2) Pipetting steps are displayed on the screen

#### INTEM exam

20 1) Reagents: in-tem® and star-tem®

21 2) Pipetting steps are displayed on the screen

#### FIBTEM exam

22 1) Reagents: r ex-tem, star-tem® and fib-tem®

23 2) Pipetting steps are displayed on the screen

#### NATEM exam

24 1) Reagents: star-tem®

25 2) Pipetting steps are displayed on the screen

#### Parameters analyzed

26 CT: clotting time, expressed in seconds  
ALPHA: alpha angle, expressed in °  
CFT: clot formation time, expressed in seconds  
MCF: Maximum clot firmness, expressed in mm  
ML: maximum lysis, expressed in %  
TPI: thrombodynamic potential index: calculated as  $[(100 \times \text{MCF}) / (100 - \text{MCF})] / \text{CFT}$

#### Statistics

- 27 1. GraphPad Prism version 8.0.0 for Windows software (GraphPad Software, San Diego, California USA, [www.graphpad.com](http://www.graphpad.com)) was used for the descriptive statistical analysis.  
A Normal distribution was tested with the Shapiro-Wilk test.  
Categorical variables were described as absolute and relative frequencies and analyzed with the Chi-square or Fisher exact test.  
Continuous variables were described as the mean  $\pm$  SD.  
Multiple comparisons among groups were performed using one-way ANOVA followed by Tukey's test for pairwise comparisons.  
Two-tailed Student's t test was used for comparisons between nonsevere and severe patients.  
In all cases, p values < 0.05 indicated statistical significance.
2. ROC curves were constructed using MedCalc software, Version 7.3.0.0 (Ostend, Belgium, URL <https://www.medcalc.org/>), to define the cutoff values and estimate the global accuracy based on the area under the ROC curve (AUC).  
Performance indices expressed as percentages (sensitivity and specificity) were obtained for each thromboelastometric parameter in all ROTEM tests.  
TG-ROC curves were assembled to confirm the selected cutoffs.

3. Decision trees were built using WEKA software (Waikato Environment for Knowledge Analysis, version 3.6.11, University of Waikato, New Zealand, URL <https://www.cs.waikato.ac.nz/ml/weka/>) to classify COVID patients and healthy controls based on selected thromboelastometric parameters.  
Leave-one-out cross-validation (LOOCV) was applied to estimate the classification accuracy and test the generalizability of the model.
4. The graphics (bar diagrams, scatter charts and decision trees) were generated using Microsoft Office Package version 2012 and GraphPad Prism software, Version 8.0